[go: up one dir, main page]

NO983100L - 4,5-dihydronaft£1,2-C|isoksazoler og derivater derav med CNS-aktivitet - Google Patents

4,5-dihydronaft£1,2-C|isoksazoler og derivater derav med CNS-aktivitet

Info

Publication number
NO983100L
NO983100L NO983100A NO983100A NO983100L NO 983100 L NO983100 L NO 983100L NO 983100 A NO983100 A NO 983100A NO 983100 A NO983100 A NO 983100A NO 983100 L NO983100 L NO 983100L
Authority
NO
Norway
Prior art keywords
dihydronaphth
derivatives
cisoxazoles
cns activity
compounds
Prior art date
Application number
NO983100A
Other languages
English (en)
Other versions
NO983100D0 (no
Inventor
Nicholas J Hrib
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of NO983100D0 publication Critical patent/NO983100D0/no
Publication of NO983100L publication Critical patent/NO983100L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

4,5-dihydronafth[l,2-c ] isoxazol- derivater av generell formel (I) hvori A, X og n er som definert og beskrevet her. Slike forbindelser er anvendbare som serotonin 5-HT,- antagonister. Disse forbindelser er anvendbare ved behandling av angst, psykiatriske forstyrrelser, kvalme, brekninger og legemiddelavhengighet.
NO983100A 1996-01-05 1998-07-03 4,5-dihydronaft£1,2-C|isoksazoler og derivater derav med CNS-aktivitet NO983100L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58331996A 1996-01-05 1996-01-05
PCT/US1996/019569 WO1997025317A1 (en) 1996-01-05 1996-12-12 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity

Publications (2)

Publication Number Publication Date
NO983100D0 NO983100D0 (no) 1998-07-03
NO983100L true NO983100L (no) 1998-09-04

Family

ID=24332609

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983100A NO983100L (no) 1996-01-05 1998-07-03 4,5-dihydronaft£1,2-C|isoksazoler og derivater derav med CNS-aktivitet

Country Status (14)

Country Link
EP (1) EP0874833A1 (no)
JP (1) JP3161737B2 (no)
KR (1) KR100308748B1 (no)
CN (1) CN1214046A (no)
AR (1) AR005347A1 (no)
AU (1) AU710059B2 (no)
BR (1) BR9612578A (no)
CA (1) CA2241845C (no)
HU (1) HUP9903706A3 (no)
IL (1) IL125197A0 (no)
NO (1) NO983100L (no)
NZ (1) NZ325587A (no)
WO (1) WO1997025317A1 (no)
ZA (1) ZA9725B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8656101A (en) * 2000-08-21 2002-03-04 Univ Georgetown 2-3-disubstituted quinuclidines as modulators of monoamine transporters and therapeutic and diagnostic methods based thereon
KR20040093061A (ko) * 2002-04-02 2004-11-04 얀센 파마슈티카 엔.브이. 치환된 아미노 이속사졸린 유도체 및 항-우울제로서의그의 용도
TW200409777A (en) * 2002-08-12 2004-06-16 Janssen Pharmaceutica Nv C-substituted tricyclic isoxazoline derivatives and their use as anti-depressants
ATE456568T1 (de) 2002-08-15 2010-02-15 Janssen Pharmaceutica Nv Kondensierte heterocyclische isoxazolinderivate und deren verwendung als antidepressiva
AU2003271567B2 (en) * 2002-08-21 2009-12-24 Janssen Pharmaceutica N.V. C6- and C9-substituted chromeno (4, 3-C) isoxazoline derivatives and their use as anti-depressants
US8025859B2 (en) 2007-05-18 2011-09-27 Cesl Limited Process for gold and silver recovery from a sulphide concentrate
KR20130036171A (ko) 2009-10-29 2013-04-11 브리스톨-마이어스 스큅 컴퍼니 트리시클릭 헤테로시클릭 화합물
ES2859478T3 (es) 2016-09-02 2021-10-04 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos sustituidos
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
KR102002633B1 (ko) 2018-07-19 2019-07-22 김태효 완충이격부가 구비된 논슬립 발의류

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2119977A1 (en) * 1971-04-23 1971-12-16 Teikoku Hormone Manufacturing Co , Ltd, Tokio Antiphlogistic and antisecretory napththisoxazoles - from 1-hydroxyim - 2-carbonyl derivs by intramolecular condensation
DK0402644T3 (da) * 1989-05-19 1996-01-02 Hoechst Roussel Pharma N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter
JPH08502958A (ja) * 1992-10-23 1996-04-02 メルク シヤープ エンド ドーム リミテツド ドーパミンレセプターサブタイプリガンド

Also Published As

Publication number Publication date
AR005347A1 (es) 1999-04-28
EP0874833A1 (en) 1998-11-04
ZA9725B (en) 1997-07-07
AU710059B2 (en) 1999-09-09
AU1412697A (en) 1997-08-01
CN1214046A (zh) 1999-04-14
JPH11510816A (ja) 1999-09-21
IL125197A0 (en) 1999-03-12
CA2241845A1 (en) 1997-07-17
HUP9903706A2 (hu) 2000-08-28
JP3161737B2 (ja) 2001-04-25
BR9612578A (pt) 1999-07-27
KR19990077033A (ko) 1999-10-25
NO983100D0 (no) 1998-07-03
CA2241845C (en) 2002-10-01
HUP9903706A3 (en) 2000-09-28
KR100308748B1 (ko) 2001-12-12
NZ325587A (en) 1999-02-25
WO1997025317A1 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
AU6944091A (en) Indole-substituted five-membered heteroaromatic compounds
DK0491664T3 (da) Indolderivater som serotonin-antagonister
CA2086434A1 (en) Quinuclidine derivatives
GR3036669T3 (en) O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same
NO983100L (no) 4,5-dihydronaft£1,2-C|isoksazoler og derivater derav med CNS-aktivitet
DK1302207T3 (da) Fremgangsmåde til at fremstille et antihypertensivt middel indeholdende et dipeptid som virkningsfuld bestanddel
ID23053A (id) Karboksamida yang digunakan sebagai agonis 5-ht <if>
ES2152379T3 (es) Dihidropiridinas condensadas y su utilizacion para la produccion de preparados farmaceuticos.
NO974155D0 (no) Ny fremgangsmåte for fremstilling av 2,3-dihydrobenzofuranolderivater
AP2002002595A0 (en) Heterocyclic amide derivatives.
DK1246790T3 (da) Substituerede 1- og 2-naphthol-Mannichbaser
TW358807B (en) Processes and intermediates for preparing 3-(1-piperazinyl)-1,2-benzisothiazole
NO934040L (no) Finfordelt silisium innbefattende et overflatebundet halogen, fremgangsmaate for fremstilling og anvendelse derav
DE59010633D1 (de) 8-alpha-ACYLAMINO-ERGOLINE, IHRE HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
TW200504081A (en) N-sulfonylaminothiazole
AU3499189A (en) Tricyclic ketones Patent to Lapse
CA2275299A1 (en) Indane or dihydroindole derivatives
NO20012538L (no) Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet
AU1370895A (en) 2'-deoxy-5-fluorouridine derivative, pharmaceutically acceptable salt thereof, process for producing the same, and antitumor drug
MX9703899A (es) Derivado de arilacrilamida.
FI891086A7 (fi) Menetelmä valmistaa farmakologisesti arvokkaita pyrido/3',4';4,5/syklohept/1,2-b/indolijohdannaisia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application